May 17 |
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
|
May 15 |
BriaCell falls on $5M stock offering
|
May 15 |
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
|
Apr 24 |
BriaCell Announces Oral and Poster Presentations at ASCO 2024
|
Apr 10 |
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
|
Apr 9 |
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
|
Mar 7 |
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
|
Mar 6 |
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
|
Feb 27 |
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
|
Feb 7 |
BriaCell shares rise on strong data from breast cancer treatment study
|